Harry W. Alcorn Jr., Chief Medical Officer at DiaMedica Therapeutics Inc. (DMAC), bought 150 shares at $4.46 ($669) on 2019-03-27, disclosed to the SEC on 2019-03-29.
Open-market purchase of $669 DMAC by Chief Medical Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| DMAC | BUY | 2019-08-16 | $19K | — | Filing → |
| DMAC | BUY | 2018-12-11 | $4K | — | Filing → |